PURPOSE: Latent Epstein-Barr virus (EBV) genomes are found in the malignant cells of approximately one-third of Hodgkin's lymphoma (HL) cases. Detection and quantitation of EBV viral DNA could potentially be used as a biomarker of disease activity. EXPERIMENTAL DESIGN: Initially, EBV-DNA viral load was prospectively monitored from peripheral blood mononuclear cells (PBMC) in patients with HL. Subsequently, we analyzed viral load in plasma from a second cohort of patients. A total of 58 patients with HL (31 newly diagnosed, 6 relapsed, and 21 in long-term remission) were tested. Using real-time PCR, 43 PBMC and 52 plasma samples were analyzed. RESULTS: EBV-DNA was detectable in the plasma of all EBV-positive patients with HL prior to therapy. However, viral DNA was undetectable following therapy in responding patients (P = 0.0156), EBV-positive HL patients in long-term remission (P = 0.0011), and in all patients with EBV-negative HL (P = 0.0238). Conversely, there was no association seen for the EBV-DNA load measured from PBMC in patients with active EBV-positive HL patients as compared with EBV-negative HL, or patients in long-term remission. EBV-DNA load in matched plasma/PBMC samples were not correlated. CONCLUSIONS: We show that free plasma EBV-DNA has excellent sensitivity and specificity, and can be used as a noninvasive biomarker for EBV-positive HL and that serial monitoring could predict response to therapy. Additional prospective studies are required to further evaluate the use of free plasma EBV-DNA as a biomarker for monitoring response to treatment in patients with EBV-positive HL.
PURPOSE: Latent Epstein-Barr virus (EBV) genomes are found in the malignant cells of approximately one-third of Hodgkin's lymphoma (HL) cases. Detection and quantitation of EBV viral DNA could potentially be used as a biomarker of disease activity. EXPERIMENTAL DESIGN: Initially, EBV-DNA viral load was prospectively monitored from peripheral blood mononuclear cells (PBMC) in patients with HL. Subsequently, we analyzed viral load in plasma from a second cohort of patients. A total of 58 patients with HL (31 newly diagnosed, 6 relapsed, and 21 in long-term remission) were tested. Using real-time PCR, 43 PBMC and 52 plasma samples were analyzed. RESULTS:EBV-DNA was detectable in the plasma of all EBV-positive patients with HL prior to therapy. However, viral DNA was undetectable following therapy in responding patients (P = 0.0156), EBV-positive HL patients in long-term remission (P = 0.0011), and in all patients with EBV-negative HL (P = 0.0238). Conversely, there was no association seen for the EBV-DNA load measured from PBMC in patients with active EBV-positive HL patients as compared with EBV-negative HL, or patients in long-term remission. EBV-DNA load in matched plasma/PBMC samples were not correlated. CONCLUSIONS: We show that free plasma EBV-DNA has excellent sensitivity and specificity, and can be used as a noninvasive biomarker for EBV-positive HL and that serial monitoring could predict response to therapy. Additional prospective studies are required to further evaluate the use of free plasma EBV-DNA as a biomarker for monitoring response to treatment in patients with EBV-positive HL.
Authors: Katherine D Westmoreland; Nathan D Montgomery; Christopher C Stanley; Nader Kim El-Mallawany; Peter Wasswa; Toon van der Gronde; Idah Mtete; Mercy Butia; Salama Itimu; Mary Chasela; Mary Mtunda; Coxcilly Kampani; N George Liomba; Tamiwe Tomoka; Bal M Dhungel; Marcia K Sanders; Robert Krysiak; Peter Kazembe; Dirk P Dittmer; Yuri Fedoriw; Satish Gopal Journal: Int J Cancer Date: 2017-03-24 Impact factor: 7.396
Authors: Do Nguyen-Van; Colm Keane; Erica Han; Kimberley Jones; Jamie P Nourse; Frank Vari; Nathan Ross; Pauline Crooks; Olivier Ramuz; Michael Green; Lyn Griffith; Ralf Trappe; Andrew Grigg; Peter Mollee; Maher K Gandhi Journal: Am J Blood Res Date: 2011-09-09
Authors: Yvette L Kasamon; Heather A Jacene; Christopher D Gocke; Lode J Swinnen; Douglas E Gladstone; Brandy Perkins; Brian K Link; Leslie L Popplewell; Thomas M Habermann; Joseph M Herman; William H Matsui; Richard J Jones; Richard F Ambinder Journal: Blood Date: 2012-02-16 Impact factor: 22.113
Authors: Jennifer J G Welch; Cindy L Schwartz; Meghan Higman; Lu Chen; Allen Buxton; Jennifer A Kanakry; Samir B Kahwash; Robert E Hutchison; Debra L Friedman; Richard F Ambinder Journal: Blood Adv Date: 2017-04-24
Authors: Jennifer A Kanakry; Hailun Li; Lan L Gellert; M Victor Lemas; Wen-son Hsieh; Fangxin Hong; King L Tan; Randy D Gascoyne; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Patrick Stiff; Bruce D Cheson; Ranjana Advani; Thomas P Miller; Brad S Kahl; Sandra J Horning; Richard F Ambinder Journal: Blood Date: 2013-02-05 Impact factor: 22.113
Authors: J Sanz; M Arango; L Senent; I Jarque; P Montesinos; A Sempere; I Lorenzo; G Martín; F Moscardó; E Mayordomo; M Salavert; C Cañigral; B Boluda; C Salazar; J L López-Hontangas; M A Sanz; G F Sanz Journal: Bone Marrow Transplant Date: 2013-12-02 Impact factor: 5.483
Authors: Jennifer A Kanakry; Aparna M Hegde; Christine M Durand; Allan B Massie; Amy E Greer; Richard F Ambinder; Alexandra Valsamakis Journal: Blood Date: 2016-01-07 Impact factor: 22.113
Authors: Vanesa Garcia; Jose Miguel Garcia; Javier Silva; Paloma Martin; Cristina Peña; Gemma Dominguez; Raquel Diaz; Mercedes Herrera; Constanza Maximiano; Pilar Sabin; Antonio Rueda; Miguel Angel Cruz; Jose Rodriguez; Miguel Angel Canales; Felix Bonilla; Mariano Provencio Journal: PLoS One Date: 2009-12-15 Impact factor: 3.240